Molecular detection of MBL and enhanced risk stratification through immunogenetic and proteomic profiling
Active Grant Awarded
- Award ID
- R01CA309413
- Recipient
-
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) UEI QKXVTWJFQKA9
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $511,551
Award facts
- Assistance listing
- 93.393 Cancer Cause and Prevention Research
- Completion date 7% complete
- Place of performance
- Netherlands
Award details come from USAspending.gov.
About this award
The National Cancer Institute, within the Department of Health and Human Services' National Institutes of Health, awarded Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) a grant totaling $511,551 on July 20, 2026, under Assistance Listing 93.393, Cancer Cause and Prevention Research. The award, Grant R01CA309413, funds molecular detection of monoclonal B-cell lymphocytosis (MBL), a precursor state to chronic lymphocytic leukemia, and enhanced risk stratification through immunogenetic and proteomic profiling.
Aim 1 evaluates whether clonality determined by sequencing the immunoglobulin heavy chain (IGH) gene repertoire from whole blood DNA can serve as a surrogate for flow cytometry, the gold standard for identifying MBL. Aim 2 identifies a novel agnostic proteomic MBL signature and tests whether proteomic biomarkers associated with CLL risk also serve as biomarkers of progression among individuals with MBL. Single-cell sequencing will characterize transcriptome profiles associated with MBL progression and identify somatic mutations contributing to progression.
Dollars obligated match the total at $511,551. The period of performance runs from the July 2026 award date to an ultimate completion date of June 30, 2031. Place of performance is the Netherlands. The source identifies no sub-recipients for this award.
The program's stated research scope includes screening, early detection and risk assessment, including biomarker discovery, development and validation, which corresponds to the Aim 2 biomarker work.
Description
- Abstract
- Monoclonal B-cell lymphocytosis (MBL) is a precursor state to chronic lymphocytic leukemia (CLL) affecting up to 5-10% of adults over age 40 in the US. Individuals with MBL are at increased risk of progression to CLL, serious infections, and nonhematological malignancies as well as have reduced humoral immune response to vaccinations. MBL is currently identified through flow cytometry, a labor-intensive and technically demanding approach that requires viable whole-blood cells. The reliance on viable blood cells limits our ability to perform MBL screening in large existing US-based cohorts. Recently, sequencing the immunoglobulin heavy chain (IGH) gene repertoire of the B-cell receptor (BCR) from whole blood DNA has emerged as an alternative approach for identifying premalignant clonality. While this approach allows US to infer the presence of MBL, no study has evaluated the accuracy ofgene clonality determined by sequencing of whole blood DNA with MBL status obtained by flow cytometry, the gold standard. Aim 1 seeks to address this critical GAP by providing insight into the viability of usinggene clonality as a surrogate to flow cytometry. Individuals with MBL are frequently unaware they have MBL, and one of the field's primary research aims has been to determine which individuals with MBL progress to CLL or other lymphoid malignancy. Cutting edge single-cell sequencing techniques will characterize transcriptome profiles associated with MBL progression and identify somatic mutations contributing to progression. Aim 2 will identify a novel agnostic proteomic MBL signature and evaluate whether proteomic molecular biomarkers associated with CLL risk are also biomarkers for progression among individuals with MBL. Because all individuals with CLL pass through the MBL stage, the next important question is to evaluate how this cllproteomic signature performs among individuals with MBL. We hypothesize that these cllproteomic molecular biomarkers will identify which individuals with MBL are at high-risk for progression to CLL or other lymphoid malignancies. Integration of MBL/CLL proteomic markers with MBL/CLL genetic risk loci through mendelian randomization will reveal the causal effect of MBL/CLL proteomic markers on CLL risk. Collectively, these aims will leverage our mayo clinic MBL cohort of over 10,500 individuals screened for MBL with stored biospecimen. Given its high prevalence, there is critical need to better understand the impact of MBL on human health. To address this need, this application aims to identify molecular factors associated with MBL progression and enable MBL status to be discerned in well established biobanks, facilitating a profound increase in knowledge regarding health implications of a highly prevalent pre-malignant condition in the US. The project outcomes will be of direct relevance to US-based leukemia/lymphoma patients and individuals in the US with MBL, with potential application to other cancer types, as well as providing new research areas for US-scientists. IT thereby has the potential to significantly advance the health sciences in the US, as well as the health of individuals with MBL across the entire globe.
Quick answers
Who received award R01CA309413?
R01CA309413 was awarded to Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) by National Cancer Institute (National Institutes of Health) on July 20, 2026.
How much is award R01CA309413 worth?
$511,551 has been obligated on R01CA309413.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award